Cargando…
No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and performed...
Autores principales: | Cetin, Hakan, Sun, Jiangwei, Almqvist, Catarina, Reichardt, Berthold, Tomschik, Matthias, Zimprich, Fritz, Fang, Fang, Ingre, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414209/ https://www.ncbi.nlm.nih.gov/pubmed/32770128 http://dx.doi.org/10.1038/s41598-020-70373-8 |
Ejemplares similares
-
Increased risk of death associated with the use of proton‐pump inhibitors in patients with dementia and controls – a pharmacoepidemiological claims data analysis
por: Cetin, H., et al.
Publicado: (2020) -
Hospital-treated infections in early- and mid-life and risk of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
por: Sun, Jiangwei, et al.
Publicado: (2022) -
Frequency and clinical features of treatment-refractory myasthenia gravis
por: Rath, Jakob, et al.
Publicado: (2019) -
The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis
por: Tomschik, Matthias, et al.
Publicado: (2023) -
Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study
por: Brozek, Wolfgang, et al.
Publicado: (2019)